Alaya.bio Reports the Acquisition of Ixaka France to Enhance its Novel in vivo CAR-T Immunotherapy Platform
Shots:
- The acquisition of Ixaka France accelerated Alaya.bio’s programs by providing preclinical PoC data depicting anti-tumoral efficacy of in vivo engineered CAR T cells in immunocompetent mouse models
- Ixaka's extensive & strong patent portfolio, preclinical data & exclusive licenses for polymeric nanoparticle technology have been acquired by Alaya.bio. The acquisition also includes viral vector bioproduction facilities & a well-equipped laboratory facility, positioning Alaya.bio for future partnerships & rapid advancement of its in vivo gene delivery technology
- Alaya.bio intends to combine its research with solid PoC generated by Ixaka and expects to cut costly and lengthy external manufacturing
Ref: Businesswire | Image: Ixaka France
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
